AD

NAFDAC Secures Full ICH Membership

NAFDAC has achieved full membership of the International Council for Harmonisation (ICH), placing Nigeria among the world’s top drug-regulatory authorities.

The upgrade was confirmed after the ICH Assembly in Singapore on November 18–19, 2025, and announced by NAFDAC’s Director-General, Prof. Mojisola Adeyeye.

She described the milestone as historic, noting that it will improve access to quality medicines, strengthen drug safety standards, and boost the credibility of locally made pharmaceuticals.

Nigeria’s journey began in 2022 when NAFDAC applied for Observer status. After capacity-building, technical training, and hosting an international ICH workshop in Lagos in April 2025, the agency met all membership requirements.

With this advancement, Nigeria becomes the 24th country and one of only 25 national regulators worldwide to attain full membership.

NAFDAC says the new status will allow Nigeria to help shape global regulatory standards, accelerate access to new therapies, and expand opportunities for local pharmaceutical companies.

Prof. Adeyeye thanked staff and the Federal Government, adding that NAFDAC remains committed to implementing ICH guidelines and strengthening public health regulation.

Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox.

We don’t spam! Read our privacy policy for more info.

More Top Stories

Tinubu, NFF Mourns Former Super Eagles Coach Adegboye Onigbinde
Lemina Header Sinks Liverpool as Galatasaray Claim Crucial First Leg Victory
D’Tigress Arrive Lyon Ahead Of 2026 FIBA Women’s World Cup Qualifying
NPFL: Rivers United Trash Bendel Insurance to Remain Top
Iranian Ambassador Speaks on Condition of Nigerians in Iran
Ogoniland Youths Protest in Port Harcourt, Demand Funding for FUET
Dangote Petroleum Refinery Slashes Petrol Price
SEC Raises Alarm Over Growing Risks as Finance Sector Expands
Rivers Ranks Third As Nightlife Economy Hits ₦900 Billion
Rivers NYSC Boss Honoured For Youth Development, Anti-Drug Advocacy

Leave a Reply

Your email address will not be published. Required fields are marked *